Marc Bourlière

26.6k citations

308 papers · 8.8k · 2 hit papers · h-index 50

Impact in

Hepatology top 0.05%
- Hepatitis C virus research
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis Viruses Studies and Epidemiology
Epidemiology top 0.1%
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies

Papers in

Hepatology 223
- Hepatitis C virus research 188
- Liver Disease and Transplantation 21
- Hepatocellular Carcinoma Treatment and Prognosis 19
- Hepatitis Viruses Studies and Epidemiology 7
Epidemiology 155
- Liver Disease Diagnosis and Treatment 112
- Hepatitis B Virus Studies 88

Co-authors: Philippe Halfon (69 shared papers)Stanislas Pol (46 shared papers)Guillaume Pénaranda (52 shared papers)Denis Ouzan (39 shared papers)Christophe Hézode (19 shared papers)Laurent Castéra (16 shared papers)Victor de Lédinghen (39 shared papers)Christophe Renou (22 shared papers)
Journals: Journal of Hepatology (70 papers)Journal of Viral Hepatitis (14 papers)Liver International (13 papers)Hepatology (11 papers)Alimentary Pharmacology & Therapeutics (10 papers)
Partner nations: France United States Germany

In The Last Decade

Marc Bourlière

292 papers receiving 8.6k citations

Marc Bourlière's Hit Papers

align trajectories log scale

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin 2014 · 396 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 New England Journal of Medicine
2009 New England Journal of Medicine

Peers

Countries citing papers authored by Marc Bourlière

Since Specialization

Citations

This map shows the geographic impact of Marc Bourlière's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Bourlière with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Bourlière more than expected).

Fields of papers citing papers by Marc Bourlière

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Bourlière. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Bourlière. The network helps show where Marc Bourlière may publish in the future.

Co-authors

The 25 scholars most cited alongside Marc Bourlière, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marc Bourlière Line = papers co-authored together Marc Bourlière links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 308 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection New England Journal of Medicine ·Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko, Peter Ferenci, Stanislas Pol, Tobias Goeser, Jean–Pierre Bronowicki, Marc Bourlière, Shahin Gharakhanian, Leif Bengtsson, Lindsay McNair, Shelley George, Tara L. Kieffer, Ann D. Kwong, Robert S. Kauffman, John Alam, Jean–Michel Pawlotsky, Stefan Zeuzem Hit paper breakdown →	2009	771
2	Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ). Gastroenterology ·Marion G. Peters, Hie‐Won Hann, Paul Martin, E. Jenny Heathcote, Peter Buggisch, R Rubin, Marc Bourlière, Kris V. Kowdley, Christian Trépo, DF Gray, Mark Sullivan, K. Kleber, Ramin Ebrahimi, S. Xiong, Carol Brosgart	2003	439
3	Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin New England Journal of Medicine ·Stefan Zeuzem, Ira M. Jacobson, Tolga Baykal, Rui Tato Marinho, Fred Poordad, Marc Bourlière, Mark Sulkowski, Heiner Wedemeyer, Edward Tam, Paul Desmond, Donald M. Jensen, Adrian M. Di Bisceglie, Peter Varunok, Tarek Hassanein, Junyuan Xiong, (unknown), Barbara DaSilva-Tillmann, Lois Larsen, Thomas Podsadecki, Barry Bernstein Hit paper breakdown →	2014	396
4	Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C New England Journal of Medicine ·John G. McHutchison, Geoffrey Dusheiko, Mitchell L. Shiffman, M. Rodríguez‐Torres, Samuel H. Sigal, Marc Bourlière, Thomas Berg, Stuart C. Gordon, Fiona Campbell, Dickens Theodore, Nicole Blackman, J.M. Jenkins, Nezam H. Afdhal	2007	328
5	Meta-analyses of FibroTest diagnostic value in chronic liver disease BMC Gastroenterology ·Thierry Poynard, Rachel Morra, Philippe Halfon, Laurent Castéra, Vlad Ratziu, Françoise Imbert‐Bismut, Sylvie Naveau, Dominique Thabut, Didier Lebrec, Fabien Zoulim, Marc Bourlière, P. Cacoub, Djamila Messous, M. Munteanu, Victor de Lédinghen	2007	239
6	Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages Clinical Chemistry ·Thierry Poynard, Philippe Halfon, Laurent Castéra, M. Munteanu, Françoise Imbert‐Bismut, Vlad Ratziu, Y. Benhamou, Marc Bourlière, Victor de Lédinghen, (unknown)	2007	194
7	Faldaprevir and Deleobuvir for HCV Genotype 1 Infection New England Journal of Medicine ·Stefan Zeuzem, Vincent Soriano, Tarik Asselah, Bronowicki Jp, Lohse Aw, Beat Müllhaupt, M. Schuchmann, Marc Bourlière, Marı́a Buti, Roberts Sk, Gane Ej, Stern Jo, Richard Vinisko, George Kukolj, Gallivan Jp, Böcher Wo, Mensa Fj	2013	173
8	Treatment of Hepatitis C Virus-Related Cirrhosis: A Randomized, Controlled Trial of Interferon Alfa–2B Versus No Treatment Hepatology ·Dominique Valla, Michèle Chevallier, Patrick Marcellin, Jean‐Louis Payen, C. Trépo, Marianne Fonck, Marc Bourlière, É. Boucher, Jean‐Philippe Miguet, David Parlier, Catherine Lemonnier, Pierre Opolon	1999	167
9	Effect of Ribavirin in Genotype 1 Patients With Hepatitis C Responding to Pegylated Interferon Alfa-2a Plus Ribavirin Gastroenterology ·Jean–Pierre Bronowicki, Denis Ouzan, Tarik Asselah, Hervé Desmorat, Jean‐Pierre Zarski, Juliette Foucher, Marc Bourlière, Christophe Renou, Albert Tran, P. Mélin, Christophe Hézode, M Chevalier, Magali Bouvier‐Alias, Stéphane Chevaliez, François Montestruc, Isabelle Lonjon‐Domanec, Jean–Michel Pawlotsky	2006	148
10	SAFE biopsy Hepatology ·Giada Sebastiani, Philippe Halfon, Laurent Castéra, Stanislas Pol, David L. Thomas, Alessandra Mangia, V. Di Marco, Mario Pirisi, M Voiculescu, Maria Guido, Marc Bourlière, Franco Noventa, A. Albertí	2009	127
11	Treatment With Ledipasvir–Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection Annals of Internal Medicine ·Massimo Colombo, Alessio Aghemo, (unknown), Jie Zhang, Hadas Dvory‐Sobol, Robert H. Hyland, Chohee Yun, Benedetta Massetto, Diana M. Brainard, John G. McHutchison, Marc Bourlière, Markus Peck‐Radosavljevic, Michael P. Manns, Stanislas Pol	2016	126
12	Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus PubMed ·Philippe Halfon, Marc Bourlière, Guillaume Pénaranda, R. Deydier, Christophe Renou, Danielle Botta‐Fridlund, Albert Tran, Isabelle Portal, Isabelle Allemand, Alessandra Rosenthal‐Allieri, Denis Ouzan	2005	121
13	Independent Prospective Multicenter Validation of Biochemical Markers (Fibrotest-Actitest) for the Prediction of Liver Fibrosis and Activity in Patients with Chronic Hepatitis C: The Fibropaca Study The American Journal of Gastroenterology ·Philippe Halfon, Marc Bourlière, R. Deydier, Danielle Botta‐Fridlund, Christophe Renou, Albert Tran, Isabelle Portal, Isabelle Allemand, J Bertrand, Alessandra Rosenthal‐Allieri, Michel Rotily, Christophe Sattonet, T Benderitter, M.C. Saint Paul, H.P. Bonnot, Guillaume Pénaranda, Claude Degott, Marie France Masseyeff, Denis Ouzan	2006	120
14	Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process Journal of Hepatology ·Xavier Adhoute, Guillaume Pénaranda, Sébastien Naudé, Jean‐Luc Raoul, Hervé Perrier, Olivier Bayle, O. Monnet, Patrick Beaurain, Christophe Bazin, Bernard Pol, G. Lefolgoc, Paul Castellani, J.-P. Bronowicki, Marc Bourlière	2014	119
15	Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study Journal of Hepatology ·Giada Sebastiani, Diego Tempesta, Giovanna Fattovich, Laurent Castéra, Philippe Halfon, Marc Bourlière, Franco Noventa, Paolo Angeli, A. Saggioro, A. Albertí	2010	115
16	Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA Journal of Hepatology ·Philippe Halfon, Hacène Khiri, V. Gérolami, Marc Bourlière, Jean Marc Feryn, Pascal Reynier, André Gauthier, G Cartouzou	1996	114
17	Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies Journal of Viral Hepatitis ·Marc Bourlière, Guillaume Pénaranda, Christophe Renou, Danielle Botta‐Fridlund, Albert Tran, Isabelle Portal, Laurence Lecomte, Patrizia Castellani, Maria‐Alessandra Rosenthal‐Allieri, René Gerolami, Denis Ouzan, R. Deydier, Claude Degott, Philippe Halfon	2006	113
18	Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders Journal of Hepatology ·Anna S. Lok, David Gardiner, Christophe Hézode, Eric Lawitz, Marc Bourlière, Gregory T. Everson, Patrick Marcellin, M. Rodríguez‐Torres, Stanislas Pol, Lawrence Serfaty, Timothy Eley, Shu-Pang Huang, Jianling Li, Megan Wind‐Rotolo, Fei Yu, Fiona McPhee, Dennis M. Grasela, C Pasquinelli	2013	112
19	Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C Journal of Hepatology ·Philippe Halfon, Yannick Bacq, A. De Muret, Guillaume Pénaranda, Marc Bourlière, Denis Ouzan, Albert Tran, Danielle Botta, Christophe Renou, M.C. Bréchot, Claude Degott, Valérie Paradis	2006	104
20	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases Alimentary Pharmacology & Therapeutics ·Giada Sebastiani, Laurent Castéra, Philippe Halfon, Stanislas Pol, Alessandra Mangia, V. Di Marco, Mario Pirisi, M Voiculescu, Marc Bourlière, A. Albertí	2011	99

About Marc Bourlière

Marc Bourlière is a scholar working on Hepatology, Epidemiology, Rheumatology, Infectious Diseases and Surgery, having authored 308 papers that have together received 8.8k indexed citations. Recurring topics across this work include Hepatitis C virus research (188 papers), Liver Disease Diagnosis and Treatment (112 papers), Hepatitis B Virus Studies (88 papers), Systemic Lupus Erythematosus Research (22 papers), Liver Disease and Transplantation (21 papers), Hepatocellular Carcinoma Treatment and Prognosis (19 papers), HIV/AIDS drug development and treatment (18 papers) and Hepatitis Viruses Studies and Epidemiology (7 papers). The work is most often cited by research in Hepatology (6.3k citations), Epidemiology (5.0k citations), Infectious Diseases (919 citations), Rheumatology (356 citations) and Transplantation (63 citations). Marc Bourlière has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Philippe Halfon, Stanislas Pol, Guillaume Pénaranda, Denis Ouzan, Christophe Hézode, Laurent Castéra, Victor de Lédinghen, Christophe Renou, Geoffrey Dusheiko and Jean–Pierre Bronowicki. Their work appears in journals such as Journal of Hepatology, Journal of Viral Hepatitis, Liver International, Hepatology and Alimentary Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Marc Bourlière

Impact in

Papers in i

In The Last Decade

Marc Bourlière

Marc Bourlière's Hit Papers

Peers

Countries citing papers authored by Marc Bourlière

Fields of papers citing papers by Marc Bourlière

All Works

About Marc Bourlière

Explore authors with similar magnitude of impact

Papers in